文献速递乳腺US

不同临床指征下非肿块型乳腺病变的超声影像特征与诊断效能

Imaging Features and Diagnostic Performance of US in Nonmass Lesions with Varying Clinical Indications.
PubMed 文献 · Radiology · 2025-01-01

该回顾性研究纳入2014年1月至2021年2月接受超声引导下活检的1152个非肿块型乳腺病变,按临床指征分为筛查、诊断性检查(DWU)和诊断性当前乳腺癌(DCBC)三组,比较超声特征阳预测值与BI-RADS评估的AUC。结果显示三组恶性率分别为10.4%、43.4%和40.1%,部分超声特征与恶性相关,DCBC组AUC(0.72)低于筛查组(0.89)和DWU组(0.88)。

要点

  • 非肿块型病变的超声特征阳预测值随临床指征不同而变化。
  • DCBC组临床BI-RADS评估AUC为0.72,低于筛查组0.89和DWU组0.88。
  • 筛查组中无超声可疑恶性特征且钼靶无异常发现的病变恶性率为2.5%-2.7%。

核心结论

  • 非肿块型病变超声特征的阳预测值因临床指征而异,并受钼靶发现、症状和病变侧别影响;新诊断乳腺癌术前超声女性的临床BI-RADS评估AUC最低。

研究设计与样本

  • 回顾性研究,纳入2014年1月至2021年2月接受超声引导下活检的1152个非肿块型病变(1152名女性,平均年龄47.7岁±11.1),按临床指征分为筛查、诊断性检查(DWU)和诊断性当前乳腺癌(DCBC)三组,以活检病理为参考标准。

关键影像表现/征象

  • 病变大小、低回声、高回声、节段性分布、异常导管改变、钙化、后方声影及无多发小囊肿与恶性相关(均P<.05)。
  • 筛查组超声特征阳预测值范围为0%-60%,DWU组为36.4%-70.7%,DCBC组为11%-100%。
  • 筛查组中无超声可疑恶性特征且钼靶无异常发现的非肿块型病变恶性率为2.5%-2.7%。

诊断标准与关键数值

  • 筛查组恶性率为10.4%(26/251),DWU组为43.4%(295/679),DCBC组为40.1%(89/222)。
  • 临床BI-RADS评估AUC:筛查组0.89,DWU组0.88,DCBC组0.72;DCBC组与筛查组、DWU组比较均P<.001。
  • 筛查组超声特征阳预测值0%-60%,DWU组36.4%-70.7%,DCBC组11%-100%。

临床应用与阅片要点

  • 解读非肿块型病变超声特征时应结合临床指征,筛查人群的阳预测值整体低于诊断性检查人群。
  • 筛查组中无超声可疑恶性特征且钼靶无异常发现时,恶性率为2.5%-2.7%。
  • 新诊断乳腺癌术前超声评估时临床BI-RADS评估AUC较低(0.72)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The diagnostic performance of breast US for nonmass lesions (NML) is not well validated. Purpose To evaluate and compare the imaging features and diagnostic performance of US for NMLs across clinical indications. Materials and Methods This retrospective study included NMLs that underwent US-guided biopsy from January 2014 to February 2021. Lesions were also classified by their clinical indications as screening, diagnostic: work-up (DWU), or diagnostic: current breast cancer (DCBC). Logistic regression was used to identify factors associated with malignancy. The positive predictive values (PPVs) of imaging features and areas under the receiver operating characteristic curve (AUCs) of the clinical Breast Imaging Reporting and Data System (BI-RADS)-based assessments were calculated and compared between clinical indication groups using the Fisher exact or χ2 test and 2000 bootstrap samples, respectively. Results A total of 1152 NMLs in 1152 women (mean age, 47.7 years ± 11.1 [SD]) were analyzed. The malignancy rates of the screening, DWU, and DCBC subgroups were 10.4% (26 of 251), 43.4% (295 of 679), and 40.1% (89 of 222), respectively. Lesion size, hypoechogenicity, hyperechogenicity, segmental distribution, abnormal duct changes, calcifications, posterior shadowing, and the absence of multiple small cysts were the features on US images that were associated with malignancy (all P < .05), with the lowest PPVs in the screening subgroup (PPVs of screening, DWU, and DCBC subgroups: 0%-60%, 36.4%-70.7%, and 11%-100%, respectively). Clinical BI-RADS assessments showed a lower AUC in the DCBC subgroup (AUC, 0.72) compared with the screening (AUC, 0.89) and DWU (AUC, 0.88) subgroups (both P < .001). In the screening subgroup, NMLs without US features suspicious for cancer and mammographic findings had malignancy rates of 2.5%-2.7%. Within the screening, DWU, and DCBC subgroups, PPVs of US features varied by findings at mammography, symptoms, and lesion laterality, respectively (P < .05). Conclusion The PPVs of the US features of NMLs differed across clinical indications and were influenced by additional factors (mammographic findings, symptoms, and lesion laterality). AUCs of clinical BI-RADS assessments were lowest in women undergoing preoperative US for newly diagnosed current breast cancer. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Dogan in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Park VY, Choi JS, Han K, et al. Imaging Features and Diagnostic Performance of US in Nonmass Lesions with Varying Clinical Indications. Radiology. 2025. PMID: 41055493. doi:10.1148/radiol.243398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。